

May 24, 2022

Dear Colleagues,

This memo is to notify you that the Cancer Genetics and Genomics Laboratory (CGL) at BC Cancer - VCC, will begin offering tumour testing for patients with metastatic prostate cancer starting the week of May 24, 2022. Key points regarding this new test offering are outlined below:

Eligibility for Testing

All patients with metastatic prostate cancer (castration sensitive or castration resistant) are eligible. This testing is not available to patients with localized disease. Only patients in whom tumour tissue testing failed or for whom there is inadequate tissue will be eligible for ctDNA testing.

Given the age of the FFPE block (for prostatectomy specimens) and small core biopsies, tissue selection is key to a successful result in these patients. Instructions for clinicians on selecting the best tissue for testing and pathologists on submitting samples are given below.

Instructions for Ordering OncoPanel and FFPE Sample Selection

For Ordering Clinicians:

- Select surgical specimen (or series) using the following guidelines
 - a. Preferred specimen - prostatectomy/TURP
 - b. Other appropriate specimens: prostate biopsy or metastatic biopsy
- For those on Cerner, OncoPanel can be ordered using test code "Prostate Panel Genetic Test Tissue"
- Fully complete and sign a [CGL Solid Tumour Requisition Molecular](#) and include the block number in the appropriate space on the requisition (see www.cancergeneticslab.ca/requisitions/)
- Fax the completed CGL requisition to the histology lab holding the FFPE block - the histology lab will send the FFPE block and requisition to BC Cancer Pathology (see attached document)

For Pathologists at the Holding Laboratory

- From within the requested surgical series, choose the block with the highest Gleason score and/or largest tumor volume
- Specimens must have a minimum of 20% tumour content within the area to be sampled
- For prostatectomy/TURP send one tumour block
- For a prostate biopsy send the two best blocks, if available
 - Core biopsies should have at least 1 mm tumour length
- De-calcified specimens are not accepted for this analysis

- More detailed guidelines on FFPE sample requirements can be found at www.cancergeneticslab.ca/guidelines/specimens/.

Other tests available for patients with prostate cancer

- ctDNA testing
 - Available to patients with metastatic prostate cancer (castration sensitive or castration resistant) who have failed tissue testing via the Oncopanel or have a specimen that is inadequate for Oncopanel
 - For those on Cerner, ctDNA testing can be ordered using test code “Prostate Panel Genetic Test”
 - Fully complete and sign a CGL Solid Tumour Requisition Molecular (see www.cancergeneticslab.ca/requisitions/)
 - The patient can have their blood drawn at any hospital blood collection site.
- Dedicated germline screen
 - All patients with metastatic prostate cancer are eligible for a dedicated germline screen. This testing is most relevant to patients with a screen negative Oncopanel or ctDNA test but is recommended for all, regardless of their tumour/ctDNA result.
 - Currently this test is available following a referral to the Hereditary Cancer Program visit: www.bccancer.bc.ca/health-professionals/clinical-resources/hereditary-cancer
 - Starting July 2022, you will be able to order multi-gene panel testing for your patients. Information on how to order germline testing for your patient will be available at <http://cancergeneticslab.ca/hereditary/>.


Test Reporting and Clinical Use

- Target TAT is 21 days from the time the specimen is received in CGL (this does not include time for the FFPE block to be shipped to the lab)
- Reports will be available in both CAIS and Cerner. Reports are not currently available in CareConnect. Reports will also be distributed via regular mail to all non-BC Cancer – VCC physicians.

For more information regarding these tests and when they should be ordered, please see the attached document (and/or visit www.cancergeneticslab.ca).

We anticipate these new test offerings will improve outcomes for this subset of patients. Please feel free to contact Dr. Krista Noonan, Dr. Christian Kollmannsberger or the CGL Geneticists for questions or problems that arise related to this initiative.

Best Regards,



Krista Noonan



Christian Kollmannsberger



Stephen Yip and the CGL team.